{
  "pmcid": "5516212",
  "sha256": "d36b6412b5a20b8918f7a785f60c9f0d6c5da907cf60ac373d2e135ab8a0fd91",
  "timestamp_utc": "2025-11-09T22:46:44.057730+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.951647577092512,
    "reading_ease": 14.820922173274624,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Troponin I Levels and Cardiovascular Complications in Postmenopausal Women Undergoing Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive 17 β-estradiol or placebo"
      },
      "Participants": {
        "score": 2,
        "evidence": "175 postmenopausal women not on estrogen replacement therapy, scheduled for coronary artery bypass grafting, with or without valve surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive 17 β-estradiol or placebo"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was major adverse cardiovascular events (MACE) within 30 days"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "175 postmenopausal women"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Troponin I levels on postoperative day 1 predicted MACE (AUC = 0.862). A cutoff of >7.6 ng/mL provided optimal sensitivity and specificity."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}